| Recruiting | Universal CAR-T Cell Therapy for MM Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | N/A | 2025-04-10 |
| Recruiting | Universal CAR-T Cell Therapy for NHL Non-hodgkin Lymphoma,B Cell | N/A | 2025-03-11 |
| Not Yet Recruiting | Long-term Follow-up Study of BRL-101 for TDT Thalassemia, Beta | — | 2024-12-08 |
| Not Yet Recruiting | The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD Autoimmune Disease | Phase 1 | 2024-11-25 |
| Not Yet Recruiting | Universal CAR-T Cell Therapy for Refractory Lupus Nephritis Lupus Nephritis | EARLY_Phase 1 | 2024-11-25 |
| Enrolling By Invitation | Clinical Study of BRL-101 in Severe SCD Sickle Cell Disease | N/A | 2024-07-29 |
| Not Yet Recruiting | Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease Sickle Cell Disease | N/A | 2024-06-14 |
| Not Yet Recruiting | Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease Sickle Cell Disease | N/A | 2024-04-20 |
| Unknown | Efficacy and Safety Evaluation of PD1-BCMA-CART Multiple Myeloma | N/A | 2024-03-01 |
| Suspended | Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells Thalassemia Major | N/A | 2023-12-25 |
| Not Yet Recruiting | Safety and Efficacy Evaluation of Next-generation CD19-UCART Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 | 2023-12-20 |
| Recruiting | Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE) | N/A | 2023-08-14 |
| Enrolling By Invitation | Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis | N/A | 2023-05-17 |
| Recruiting | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma Non-hodgkin Lymphoma,B Cell | Phase 1 | 2023-04-25 |
| Recruiting | Long-term Follow-up Study of BHC001 for TDT Thalassemia, Beta | — | 2022-12-14 |
| Enrolling By Invitation | Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia Beta-Thalassemia | Phase 1 / Phase 2 | 2022-11-01 |
| Withdrawn | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma Multiple Myeloma | N/A | 2021-11-01 |
| Terminated | β-globin Restored Autologous HSC in β-thalassemia Major Patients β-thalassemia Major | Phase 1 / Phase 2 | 2021-11-01 |
| Completed | Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells β Thalassemia Major | N/A | 2020-10-01 |
| Suspended | LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer Castrate-Resistant Prostate Cancer | Phase 1 | 2020-07-16 |
| Completed | PD1-CD19-CART in Patients With r/r B-cell Lymphoma B-cell Lymphoma | N/A | 2020-03-13 |
| Suspended | Efficacy and Safety Evaluation of BCMA-UCART Multiple Myeloma | N/A | 2019-11-01 |
| Suspended | Safety and Efficacy Evaluation of CD19-UCART Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) | N/A | 2019-06-01 |
| Completed | CD19-CART Treatment for ALL Acute Leukemia | Phase 1 / Phase 2 | 2018-08-01 |